Skip to Content
  • Previous Rank
  • Revenues ($M)
  • Revenue Percent Change
  • Profits ($M)
  • Profits Percent Change
  • Assets ($M)
  • Employees

The 133-year-old health care conglomerate makes everything from Band-Aids and baby shampoo to contact lenses and hip implants, but its $40.7 billion pharmaceutical division is what drove the most revenue growth in 2018. The company’s cancer and immunology drugs sold especially well. J&J’s medical device division eked out sales growth despite divestitures, as did the company’s consumer business, which continues to see challenges in its recently relaunched baby care line. The company faces more than 13,000 lawsuits—and federal inquiries—over the safety of its talc-based baby powder. (J&J maintains the product is perfectly safe.)

Company Info

Alex Gorsky
CEO Title
Chairman & Chief Executive Officer
Health Care
HQ Location
New Brunswick, N.J.
Years on Fortune 500 List65
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Johnson & Johnson Rank History


Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$81,581.06.7%
Profits ($M)$15,297.01076.7%
Assets ($M)$152,954.0-
Total Stockholder Equity ($M)$59,752.0-

Profit Ratios

Profit as % of Revenues18.8%
Profits as % of Assets10.0%
Profits as % of Stockholder Equity25.6%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)5.61
EPS % Change (from 2017)1093.6%
EPS % Change (5 year annual rate)3.1%
EPS % Change (10 year annual rate)2.1%

Total Return

Total Return to Investors (2018)-5.2%
Total Return to Investors (5 year, annualized)10.0%
Total Return to Investors (10 year, annualized)11.3%